Carlsmed, Inc. ( (CARL) ) has released its Q2 earnings. Here is a breakdown of the information Carlsmed, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Carlsmed, Inc. is a medical technology company specializing in AI-enabled personalized spine surgery solutions, aiming to enhance patient outcomes and reduce healthcare costs in spine surgery. In its recent earnings report, Carlsmed announced a significant 99% year-over-year growth in Q2 2025 revenue, reaching $12.1 million, driven by the adoption of its aprevo® technology platform. The company also completed its first personalized cervical spine surgery, marking a milestone in its technological advancements. Key financial highlights include a gross profit of $8.9 million and a gross margin of 73.4%, despite a slight decrease from the previous year due to production fees. Operating expenses rose to $15.4 million, reflecting increased investment in R&D and marketing to support growth. Despite a net loss of $6.8 million, Carlsmed’s cash position was bolstered by proceeds from its recent IPO. Looking ahead, Carlsmed projects full-year revenue between $45.5 million and $47.5 million, indicating continued strong growth as it aims to establish its technology as the new standard in spine fusion surgery.